Evidence map›Paper›PMID 38755605›Full record

SynthesisBMC pulmonary medicine2024

Associations between immune cell phenotypes and lung cancer subtypes: insights from mendelian randomization analysis.

Jin-Min Zheng, Chen-Xi Lou, Yu-Liang Huang, Wen-Tao Song, Yi-Chen Luo, Guan-Yong Mo, Lin-Yuan Tan, Shang-Wei Chen, Bai-Jun Li

Abstract readMeta-Analysis
In one paragraph

Synthesis in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Genetic evidence for POR-mediated ferroptosis in lung cancer prevention: a causal role of granulocyte modulation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jin-Min Zheng *Department of Surgery, Guangxi Medical University, Nanning, Guangxi, China.
Chen-Xi Lou *Department of Surgery, Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
Yu-Liang HuangDepartment of Surgery, Guangxi Medical University, Nanning, Guangxi, China.
Wen-Tao SongDepartment of Surgery, Youjiang Medical University For Nationalities, Baise, Guangxi, China.
Yi-Chen LuoDepartment of thoracic surgery, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Guan-Yong MoDepartment of thoracic surgery, Guilin Medical University, Guilin, Guangxi, China.
Lin-Yuan TanDepartment of Surgery, Guangxi Medical University, Nanning, Guangxi, China.
Shang-Wei ChenDepartment of thoracic surgery, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China. ShangweiChen_gxmu@126.com.
Bai-Jun LiDepartment of thoracic surgery, Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China. libaijun1979@126.com.

Funding

Guangxi Key Research and Development Program Guike AB23026006National Natural Science Foundation of China Grant no. 82060078the Guangxi Health Commission, and the Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project grant no. S2022001the Natural Science Youth Fund of Guangxi Zhuang Autonomous Region, China 2022GXNSFBA035497
6 · The paper itself

Abstract

introductionLung cancer is a common malignant tumor, and different types of immune cells may have different effects on the occurrence and development of lung cancer subtypes, including lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). However, the causal relationship between immune phenotype and lung cancer is still unclear.

methodsThis study utilized a comprehensive dataset containing 731 immune phenotypes from the European Bioinformatics Institute (EBI) to evaluate the potential causal relationship between immune phenotypes and LUSC and LUAD using the inverse variance weighted (IVW) method in Mendelian randomization (MR). Sensitivity analyses, including MR-Egger intercept, Cochran Q test, and others, were conducted for the robustness of the results. The study results were further validated through meta-analysis using data from the Transdisciplinary Research Into Cancer of the Lung (TRICL) data. Additionally, confounding factors were excluded to ensure the robustness of the findings.

resultsAmong the final selection of 729 immune cell phenotypes, three immune phenotypes exhibited statistically significant effects with LUSC. CD28 expression on resting CD4 regulatory T cells (OR 1.0980, 95% CI: 1.0627-1.1344, p < 0.0001) and CD45RA + CD28- CD8 + T cell %T cell (OR 1.0011, 95% CI: 1.0007; 1.0015, p < 0.0001) were associated with increased susceptibility to LUSC. Conversely, CCR2 expression on monocytes (OR 0.9399, 95% CI: 0.9177-0.9625, p < 0.0001) was correlated with a decreased risk of LUSC. However, no significant causal relationships were established between any immune cell phenotypes and LUAD.

conclusionThis study demonstrates that specific immune cell types are associated with the risk of LUSC but not with LUAD. While these findings are derived solely from European populations, they still provide clues for a deeper understanding of the immunological mechanisms underlying lung cancer and may offer new directions for future therapeutic strategies and preventive measures.

Indexed as

Adenocarcinoma of LungLung NeoplasmsMendelian Randomization AnalysisPhenotypeCarcinoma, Squamous CellCD28 AntigensCD8-Positive T-LymphocytesHumansReceptors, CCR2CD28 AntigensReceptors, CCR2Immune cellLung adenocarcinomaLung squamous cell carcinomaMendelian randomization analysis

Identifiers

PMID38755605
PMCPMC11100125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.